|
EP0279862B1
(en)
|
1986-08-28 |
1993-11-03 |
Teijin Limited |
Cytocidal antibody complex and process for its preparation
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP1286700A2
(en)
|
2000-06-01 |
2003-03-05 |
Universite Catholique De Louvain |
Tumor activated prodrug compounds
|
|
KR20030064275A
(ko)
*
|
2000-06-29 |
2003-07-31 |
메르크 파텐트 게엠베하 |
면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
WO2002030460A2
(en)
|
2000-10-09 |
2002-04-18 |
Isis Innovation Ltd. |
Therapeutic antibodies
|
|
US6942853B2
(en)
*
|
2001-01-09 |
2005-09-13 |
Queen Mary And Westfield College |
Latent fusion protein
|
|
US20040109855A1
(en)
|
2002-07-23 |
2004-06-10 |
Herman Waldmann |
Therapeutic antibodies with reduced side effect
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
US20060024272A1
(en)
|
2004-07-29 |
2006-02-02 |
Large Scale Biology Corporation |
C-terminally truncated interferon
|
|
MX2007014889A
(es)
*
|
2005-05-26 |
2008-02-19 |
Schering Corp |
Fusion de interferon-inmunoglobulina g.
|
|
JP2009529522A
(ja)
|
2006-03-10 |
2009-08-20 |
ディアト |
酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
US20100297081A1
(en)
|
2007-12-18 |
2010-11-25 |
Huang Yanshan |
Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
AU2010215761B2
(en)
|
2009-02-23 |
2017-04-06 |
Cytomx Therapeutics, Inc |
Proproteins and methods of use thereof
|
|
EP2553101A4
(en)
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
PROTEASE-ACTIVATED CYTOKINES
|
|
PT2646464E
(pt)
|
2010-12-03 |
2015-10-05 |
Adamed Sp Zoo |
Proteína de fusão anticancerígena
|
|
EP2665486B1
(en)
|
2011-01-18 |
2019-12-25 |
Bioniz, LLC |
Compositions for modulating gamma-c-cytokine activity
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
CN104363919A
(zh)
*
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
NZ718283A
(en)
|
2013-09-25 |
2022-05-27 |
Cytomx Therapeutics Inc |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
US9562073B2
(en)
*
|
2014-01-31 |
2017-02-07 |
Cytomx Therapeutics, Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
GB201411506D0
(en)
*
|
2014-06-27 |
2014-08-13 |
Univ London Queen Mary |
Modified latency associated protein construct
|
|
DK3215528T3
(da)
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
CN109562143A
(zh)
|
2016-05-06 |
2019-04-02 |
王牧林 |
白细胞介素组合及其用途
|
|
MY203000A
(en)
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
JP2020528878A
(ja)
|
2017-06-20 |
2020-10-01 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
がん治療用インターフェロンプロドラッグ
|
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
JP7404252B2
(ja)
|
2017-11-08 |
2023-12-25 |
ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド |
生体分子のコンジュゲートおよびその使用
|
|
EP3707162A1
(en)
|
2017-11-10 |
2020-09-16 |
Agency for Science, Technology and Research |
Il2rbeta/common gamma chain antibodies
|
|
CA3086040A1
(en)
|
2017-12-19 |
2019-06-27 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
WO2020113403A1
(en)
|
2018-12-04 |
2020-06-11 |
Beijing Percans Oncology Co. Ltd. |
Cytokine fusion proteins
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
US20210253672A1
(en)
|
2018-05-30 |
2021-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule containing single domain antibody
|
|
EP3810530B2
(de)
|
2018-06-21 |
2026-03-18 |
TGW Logistics GmbH |
Lager- und kommissioniersystem sowie verfahren zum kommissionieren von auftragswaren aus einer hängetasche und einem anderen ladehilfsmittel
|
|
AU2019288484B2
(en)
|
2018-06-22 |
2024-06-20 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
MX2021003580A
(es)
|
2018-09-28 |
2021-10-13 |
Pf Medicament |
Nuevas inmunocitocinas para el tratamiento contra el cancer.
|
|
SG11202104136YA
(en)
|
2018-10-23 |
2021-05-28 |
Dragonfly Therapeutics Inc |
Heterodimeric fc-fused proteins
|
|
CA3120327A1
(en)
|
2018-12-06 |
2020-06-11 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
WO2020123980A1
(en)
|
2018-12-14 |
2020-06-18 |
Proviva Therapeutics (Hong Kong) Limited |
Il-15 compositions and methods of use thereof
|
|
EP3955957A1
(en)
|
2019-04-15 |
2022-02-23 |
Qwixel Therapeutics LLC |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
EP3969035A4
(en)
|
2019-05-14 |
2023-06-21 |
Werewolf Therapeutics, Inc. |
SEPARATION UNITS AND METHODS AND THEIR USE
|
|
US20220227837A1
(en)
|
2019-05-24 |
2022-07-21 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2 compositions and methods of use thereof
|
|
CN114127277A
(zh)
|
2019-06-05 |
2022-03-01 |
中外制药株式会社 |
蛋白酶底物和包含蛋白酶切割序列的多肽
|
|
CA3141626A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
EP3997115A4
(en)
|
2019-07-12 |
2023-11-22 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2 compositions and methods of use thereof
|
|
WO2021016599A1
(en)
|
2019-07-25 |
2021-01-28 |
Trutino Biosciences Inc |
Il-2 cytokine prodrugs comprising a cleavable linker
|
|
BR112022001320A2
(pt)
|
2019-07-25 |
2022-04-12 |
Univ Chicago |
Composições e métodos compreendendo agentes terapêuticos ativados por protease
|
|
CA3148505A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
US20220289822A1
(en)
|
2019-08-21 |
2022-09-15 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
AU2020353235A1
(en)
|
2019-09-28 |
2022-03-31 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
MX2022005666A
(es)
|
2019-11-14 |
2022-10-07 |
Werewolf Therapeutics Inc |
Polipeptidos de citocina activables y metodos de uso de los mismos.
|
|
WO2021113577A1
(en)
|
2019-12-05 |
2021-06-10 |
Immune Targeting Inc. |
Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
|
|
MX2022007202A
(es)
|
2019-12-13 |
2022-10-07 |
Cugene Inc |
Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
|
|
WO2021127487A2
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
BR112022013993A2
(pt)
|
2020-01-15 |
2022-10-11 |
Trutino Biosciences Inc |
Profármacos de citocina compreendendo um ligante clivável
|
|
JP7773991B2
(ja)
|
2020-03-23 |
2025-11-20 |
ザイムワークス ビーシー インコーポレイテッド |
マスクされたｉｌ１２融合タンパク質及びその使用方法
|
|
WO2021202354A1
(en)
|
2020-03-30 |
2021-10-07 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il-15 compositions and methods of use thereof
|
|
EP4126246A4
(en)
|
2020-04-01 |
2024-05-15 |
Xilio Development, Inc. |
MASKED IL-15 CYTOKINE AND THEIR DECOMPOSITION PRODUCTS
|
|
TW202204388A
(zh)
|
2020-04-01 |
2022-02-01 |
美商艾希利歐發展股份有限公司 |
經遮蔽之il-2細胞激素及其裂解產物
|
|
JP7771076B2
(ja)
|
2020-04-01 |
2025-11-17 |
エクシリオ デベロップメント， インコーポレイテッド |
マスクされたｉｌ－１２サイトカイン及びその切断産物
|
|
WO2021207669A1
(en)
|
2020-04-10 |
2021-10-14 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
EP4143220A4
(en)
|
2020-04-30 |
2024-05-29 |
Immune Targeting Inc. |
COMPOSITION OF ACTIVATABLE IL2 AND METHODS OF USE
|
|
CA3178657A1
(en)
|
2020-05-19 |
2021-11-25 |
William Winston |
Activatable il-12 polypeptides and methods of use thereof
|
|
BR112023018735A2
(pt)
|
2021-03-16 |
2023-11-28 |
Cytomx Therapeutics Inc |
Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
|
|
EP4695281A1
(en)
*
|
2023-04-12 |
2026-02-18 |
CytomX Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|